Notice type: 3rd Party Publications
This update is to inform healthcare professionals of a recent update to the product information for Implanon NXT, 68mg implant for subdermal use (etonogestrel). This update relates to extending the use of Implanon NXT to allow insertion immediately postpartum (IPP) and immediately postabortion (IPA).
Please see the document linked below for further information.
Authorisation Holder:
Organon Pharma (Ireland) Limited